Global Antibody Market: Drivers and Restraints
The global demand for the antibody is likely to remain moderate in the coming years. The increasing occurrence of chronic diseases such as diabetes, cancer, and autoimmune diseases is promising the manufacturers to invest in research and development activities that are affecting antibodies. Growing aging population prone to immunological disorders increases the demand for the antibody. The frequent occurrence of infectious diseases across the globe coupled with the rising popularity of protein therapeutics is fuelling the sales of the antibodies drugs over the forecasted period.
Rising application of widespread knowledge and personalized medicines are likely to boost the growth of global antibody market in the near future. The sales of the antibody are likely to remain at a steady rate during the projected period. An introduction of a substitute therapeutic drugs is predicted to fuel the growth of the antibody market in the coming years.
However, factors such as high cost of production and risk of side effects related to antibodies create a negative impact on the growth of the market.
Global Antibody Market: Segmental Analysis
On the basis of product type, the global market for the antibody is segmented into IgA, IgM, and IgG. Based on the application, the market is further segmented into Diagnostic, Therapeutic, and Research.
Global Antibody Market: Geographical Overview
North America is expected to dominate the market for antibody in terms of trend and revenue. The market is likely to grow at a moderate rate over the assessment period. Presence of top players and the existence of well-established healthcare infrastructure are likely to propel the growth of the market in North America. Europe is likely to grow the antibody market in the years to come. The Asia Pacific is also expected to show remarkable growth over the anticipated period.
Global Antibody Market: Key Players
Some of the leading players operating into the global market for antibody are Seattle Genetics, Roche, Alexion Pharmaceuticals, Johnson & Johnson, Sanofi, Merck, AstraZeneca, AbbVie, Biogen, Amgen, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Bayer, and Lilly.
Global Antibody Market: Competitive Analysis
The manufacturers are mainly concentrated in East China, Central China, and Southwest China, where East China is likely to hold the largest market share. There are also some of the local players functioning in China such as Wondfo, Fapon, MACCURA, Genscript, Leadman, and Kitgen. Fapon is one of the leading players in China.
Johnson & Johnson to Post Q1 2020 Earnings of $2.40 per Share
Leerink Swann has also issued estimations for Johnson & Johnson's Q2 2020 earnings at $2.35 Earnings per Share and Q4 2020 earnings at $2.12 Earnings per Share. The company has late posted his quarterly ended data on January 22, 2019. The company's EPS for the quarter is $1.97, and consensus estimates of $1.95 by $0.02. The company's net profit is 18.75% and an (ROE) return on equity is 35.09%. Johnson & Johnson earned revenue of $20.39 billion during the quarter, compared with a consensus estimate of $20.27 billion. The company's earnings were up 1.0% compared to the same quarter last year.
Full Report Overview@ https://www.qyresearch.com/index/detail/202248/Global-Antibody-Sales-market